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Abstract
The clinical features of psoriasis, characterized by sharply demarcated scaly erythematous plaques, are typically so
distinctive that a diagnosis can easily be made on these grounds alone. However, there is great variability in treatment
response between individual patients, and this may reflect heterogeneity of inflammatory networks driving the disease. In
this study, whole-genome transcriptional profiling was used to characterize inflammatory and cytokine networks in 62
lesional skin samples obtained from patients with stable chronic plaque psoriasis. We were able to stratify lesions according
to their inflammatory gene expression signatures, identifying those associated with strong (37% of patients), moderate
(39%) and weak inflammatory infiltrates (24%). Additionally, we identified differences in cytokine signatures with
heightened cytokine-response patterns in one sub-group of lesions (IL-13-strong; 50%) and attenuation of these patterns in
a second sub-group (IL-13-weak; 50%). These sub-groups correlated with the composition of the inflammatory infiltrate, but
were only weakly associated with increased risk allele frequency at some psoriasis susceptibility loci (e.g., REL, TRAF3IP2 and
NOS2). Our findings highlight variable points in the inflammatory and cytokine networks known to drive chronic plaque
psoriasis. Such heterogeneous aspects may shape clinical course and treatment responses, and can provide avenues for
development of personalized treatments.
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Introduction
Psoriasis is a chronic inflammatory skin disease characterized by
marked proliferation of keratinocytes leading to pronounced
epidermal hyperplasia, elongation of rete ridges and hyperkera-
tosis. The most common form of psoriasis, chronic plaque psoriasis
(Psoriasis vulgaris), involves relatively stable occurrence and
progression of sharply demarcated lesions, usually on the trunk
and extremities, which share a combination of trademark
histological features, including tortuous and dilated dermal
capillaries, loss of the epidermal granular layer, and accumulation
of neutrophils beneath parakeratotic scale [1,2]. Severity and
progression of psoriasis, as well as its response to treatment, is
variable among patients [3–5]. This may reflect heterogeneity in
patient-specific inflammatory networks, although at present,
factors that account for variability in disease presentation,
progression and treatment response are not well understood [6,7].
The transcriptome of psoriasis lesions has been evaluated using
high-throughput methods, and in principle, such information
could provide an objective basis for identifying molecular sub-
types of psoriasis, while providing insight into factors that account
for variability among patients [8–15]. The most widely held model
of psoriasis pathogenesis proposes that keratinocyte hyper-
proliferation is triggered by cutaneous lymphocyte infiltration,
activation and differentiation of inflammatory cells, including T-
cells, macrophages, and dendritic cells, and that these events
generate a localized cytokine environment that both sustains and
reinforces the pathogenic cascade [16]. Key factors that underlie
this process, i.e., the presence of inflammatory cells and cytokines,
can be characterized and modeled by algorithms applied to
genome-wide expression patterns [13,17,18]. Objective and
biologically meaningful differentiation among individual patients
may therefore be achieved on the basis of functional genomic data
and development of computational approaches. Previous analyses
of the psoriasis transcriptome have identified genes differentially
expressed between lesional and non-lesional skin, leading to the
identification of numerous genes for which expression is robustly
associated with psoriatic lesions [8–15]. This analytical approach,
however, is implicitly oriented towards those features of genome-
wide expression profiles that exhibit least variability among
lesional skin samples from patients, filtering out heterogeneous
expression patterns and their inter-patient variability.
In this study, we have analyzed genome-wide expression
patterns in psoriasis from a new perspective, with the distinct
aim of characterizing heterogeneity among lesional skin samples in
terms of biologically meaningful patterns embedded within
transcriptome data. For this purpose, we utilized an algorithm
developed for the calculation of ‘‘inflammation profiles’’ from
microarray data, which aims to explain expression differences
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34594between lesional and non-lesional skin in terms of shifts in the
composition of cellular infiltrate [18]. In addition, sets of cytokine-
responsive transcripts, identified from experiments performed with
cultured keratinocytes, are used to analyze differences in cytokine
activity among psoriasis lesions [19]. Based on these patterns, we
characterize the spectrum of molecular phenotypes associated with
the clinical presentation of chronic plaque psoriasis. These
analytical methods can be readily applied on a larger scale, and
we anticipate that this will facilitate development of personalized
treatment regimes [6,20,21].
Results
Psoriasis lesions from 62 patients can be classified into
three sub-groups (weak, moderate and strong
inflammatory infiltrate signatures)
We evaluated genome-wide expression patterns in lesional (PP)
and non-lesional (PN) skin biopsies obtained from 62 patients with
chronic plaque psoriasis. For each of 54,675 probe sets (Affymetrix
Human Genome 133 Plus 2.0 array), we calculated the difference
in gene expression between paired PP and PN skin from individual
patients. We then calculated an ‘‘inflammation profile’’ for each
patient, based upon PP versus PN expression level differences for
‘‘signature transcripts’’ that are highly expressed within specific
cell types in skin or the immune system (Figures 1 and S1) [18].
Among the 62 patients, the most consistent feature was elevated
expression of keratinocyte-associated transcripts in PP skin
compared with PN skin (significant in 91.9% of subjects; see
Figures 1 and S1). Additionally, in PP skin from most subjects, we
noted elevated expression of transcripts associated with CD34+
cells (64.5%), CD4+ T-cells (58.1%), cd T-cells (56.5%) and CD3+
T-cells (56.5%) (Figures 1 and S1). These consistent features of
inflammation profiles correspond well with known histological
properties of psoriasis lesions [1], and we have used immunohis-
tochemistry to confirm the presence of these and other cell types in
PP samples (Figure S2). We did not detect statistically significant
outliers among the 62 subjects (Grubb’s test, P$0.45; Figure S3).
However, we noted substantial heterogeneity with respect to some
cell types (e.g., monocytes, macrophages and dendritic cells), with
significant patterns detected in only a fraction (,50%) of the
patient cohort (Figures 1 and S1).
The inflammatory signatures from each patient were further
analyzed by hierarchical cluster analysis. The clustering solution
suggested at least three sub-groups, including 23 patients with
strong inflammatory infiltrate signatures (blue labels; Figures 1, S1
and S4), 24 subjects with moderate signatures (red labels; Figures 1,
S1 and S4), and 15 subjects with weak signatures (green labels;
Figures 1, S1 and S4). The exact number of sub-groups detected
by this approach depends upon the ‘‘height’’ or inter-signature
distance at which the dendrogram tree is ‘‘cut’’ (Figures 1 and S1).
As a guide for choosing this height, we analyzed an independent
dataset from the study of Yao et al. [11], which consisted of PP and
PN expression profiles from 28 patients (Figure S5) [11]. These
data also suggested the presence of three patient sub-groupings
with characteristics resembling those of the strong, moderate and
weak inflammatory groups identified in our dataset of 62 patients.
This indicated that a three-group partitioning of inflammatory
patterns can be replicated in an external patient cohort, and along
these lines, we chose a dendrogram ‘‘cut’’ that yielded three sub-
groups (Figure S5).
The 23 patients with strong inflammatory signatures were
characterized by robust trends among cell types consistently
significant in all inflammation profiles (e.g., keratinocytes, cd T-
cells, CD4+ T-cells, CD3+ T-cells and CD34+ cells), but in
addition, exhibited strong trends with respect to NK-cells,
monocytes, macrophages, dendritic cells and bone-marrow
progenitor cells (Figures 1, S1 and S4). The 24 patients with
moderate inflammatory signatures, in contrast, exhibited weaker
trends with respect to this latter group of cell types (Figures 1, S1
and S4). There was a strong distinction between the 15 weak
inflammatory signatures and those from the other two groups
(Figures 1, S1 and S4). Among patients with weak signatures, even
the most consistent features among subjects were notably
attenuated (e.g., CD4+ T-cells, cd T-cells, NK-cells, CD34+ cells
and progenitor cells), and there was quantitatively depressed
elevation of transcripts associated with cell types from the
monocyte-macrophage and monocyte-DC lineages (Figures 1, S1
and S4).
Infiltrating immune cells drive keratinocyte responses in
psoriasis [1,22,23], but there was no strong tendency for weaker
inflammatory signatures to associate with attenuated keratinocyte
responses. However, the proportion of keratinocyte signature
transcripts elevated in PP samples relative to PN samples varied
from 64.3% (95% confidence interval: 61.3%–67.3%) to 94.0%
(92.5%–95.5%) (Figure S6A). Among CD4+ T-cell and DC-
associated transcripts, the proportion of PP-elevated transcripts
varied from 55% to 90%, with weak and moderately strong
inflammatory signatures mainly present in the lower tail of the
distribution (Figures S6B and S6C).
Psoriasis lesions from 62 patients can be classified into
two sub-groups (IL-13-strong and IL-13-weak) based
upon expression patterns of cytokine-responsive
transcripts
Dermal infiltration by inflammatory cells facilitates develop-
ment of a cytokine environment that reinforces inflammatory
cascades and contributes to keratinocyte hyper-proliferation [16].
This cytokine environment is one factor accounting for in vivo
transcriptome differences between lesional (PP) and non-lesional
(PN) skin samples obtained from a given patient [13,24].We
expected that the in vivo abundance and activity of cytokines would
be linked to characteristic gene expression responses, which could
be used as a transcriptional readout to infer upstream signaling
activity associated with individual cytokines (e.g., see algorithm
presented by Shimoni et al. [19]). We therefore analyzed PP versus
PN differences in terms of cytokine activity signatures, which were
calculated using cytokine-responsive transcripts identified from
cultured keratinocytes exposed to cytokines (Figures 2 and S7).
A total of 32 signatures were considered, where each signature
was based upon PP versus PN expression differences for the 1000
transcripts most strongly induced or repressed by a given cytokine
(Figures 2 and S7). For 14 of the 32 signatures, signature scores
among patients were significantly correlated with fold-change
estimates that reflect the PP vs. PN difference in steady state
mRNA level of the associated cytokine (Table S1). However,
trends associated with cytokine-encoding mRNA levels did not
always correspond with those discerned from cytokine-responsive
transcripts. IL-13-induced transcripts, for instance, were largely
decreased in PP skin of subjects for which expression of IL-13
mRNA was elevated (rs=20.66); conversely, IL-13-repressed
transcripts were largely increased in PP skin from those subjects
with elevated IL-13 mRNA (rs=0.67) (Table S1).
Transcripts induced or repressed by cytokines in vitro exhibited
clear directional trends with respect to expression level differences
between PP and PN samples (Figures 2 and S7). We identified
seven cytokines for which gene expression signatures were most
consistently associated with PP versus PN expression differences,
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each of these cases, for more than 85% of subjects, either cytokine-
induced transcripts were disproportionately elevated in PP relative
to paired PN samples, and/or cytokine-repressed transcripts were
disproportionately decreased in PP samples (Figures 2 and S7).
The IL-19-induced cytokine signature, for instance, was the most
Figure 1. Sub-division of psoriasis lesions into strong, moderate and weak inflammatory groups based on genome-wide
expression profiles. The heatmap displays intensity of inflammatory gene expression patterns in psoriatic plaques obtained from 62 subjects
(rows) with respect to 24 different cell types (columns; immunocytes and dermal cells). Strong inflammatory signatures are denoted by blue subject
labels (23/62 subjects), moderate signatures by red labels (24/62) and weak signatures by green labels (15/62). Lesional (PP) and non-lesional (PN) skin
from each subject was analyzed by microarray to identify PP-increased and PP-decreased transcripts. Chart colors denote the behavior of 1000
‘‘signature transcripts’’ associated with each cell population (see scale and Methods). Percentage values (bottom) denote the total fraction of subjects
with a significant bias towards PP-increased expression among signature transcripts (black dots). Subject labels include a patient identifier with sex
(M or F) and age. Asterisk symbols denote subjects with IL-13-weak gene expression signatures (see text and Figure 2). An expanded version of this
figure is provided as supplemental material (Figure S1).
doi:10.1371/journal.pone.0034594.g001
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transcripts induced by IL-19 treatment in vitro, 75.8% were, on
average, elevated in lesional skin as compared to non-lesional skin,
and this percentage was significantly large in all but one patient
from the cohort (i.e., 98.4% of patients). These robust trends
related to IL-1b, IL-17A, IL-19, IL-20, IL-22, IL-24 and IFN-c
were replicated with respect to an independent dataset with 28
patients (Figure S8) [11].
Figure 2. Sub-division of psoriasis lesions into IL-13-strong and IL-13-weak groups based on genome-wide expression profiles. We
identified 32 sets of 1000 cytokine-responsive transcripts based upon in vitro exposure of keratinocytes to cytokines. For each set (columns) and
subject (rows), chart colors denote the ratio of PP-increased to PP-decreased transcripts (see scale and Methods). Up-triangles indicate significant bias
towards PP-increased expression (FDR-adjusted P,0.05 and ratio value .1.50). Down-triangles indicate significant bias towards PP-decreased
expression (FDR-adjusted P,0.05 and ratio value ,0.667). Percentage values (bottom) denote the total fraction of subjects with significant patterns
in either direction. Asterisk symbols identify subjects associated with the IL-13-weak group (bottom of dendrogram; 31/62 subjects). All other
subjects are associated with IL-13-strong patterns (top of dendrogram; 31/62 subjects). Subject label colors are consistent with those in Figure 1
(strong, moderate and weak inflammatory groups). An expanded version of this figure is provided as supplemental material (Figure S7).
doi:10.1371/journal.pone.0034594.g002
Heterogeneity in Chronic Plaque Psoriasis
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e34594Only a fraction of cytokine activity signatures followed
consistent trends among subjects. We clustered cytokine signatures
using hierarchical methods and identified two patient sub-groups
(Figures 2, S7 and S9). One sub-group included 31 subjects and
exhibited an IL-13-strong pattern, with consistent expression level
differences (PP versus PN) among transcripts responsive to
keratinocyte treatment with IL-13 (also IFN-a, TNF, IL1-a, IL-
17A, and IFN-c; see Figures 2 and S7, upper branch of
dendrogram, no asterisk; Figure S9). The other sub-group
included 31 subjects with an IL-13-weak pattern (along with
weaker IL1-a, IL-17A, and IFN-c responses) and attenuation of
transcriptional response patterns associated with these cytokines
(Figures 2, S7 and S9). Three of the 62 subjects were identified as
outliers (i.e., 4284, 4697 and 4163; Grubb’s test, P=1.95610
212)
(Figure S10), but each of these tended to follow an IL-13-strong
pattern (Figures 2, S7 and S9). Analysis of an independent dataset
identified similar trends with respect to IL-13, with 21 subjects
approximating the IL-13-weak pattern and 7 approximating the
IL-13-strong pattern (Figure S8). However, the IL-13-related
patterns were not as consistently linked with corresponding trends
for other cytokines (e.g., IFN-a, TNF, IL1-a, IL-17A, and IFN-c),
and the clustering pattern did not identify two patient sub-groups
as shown in Figures 2 and S7.
Local accumulation of key cytokines is both a driver and
consequence of inflammatory events, and this connection between
cytokine and inflammatory networks was discernible from our
analysis (Figures 3 and 4). The behavior of IL-13-repressed
transcripts, for instance, was the most variable among the 62
patients (Figure 3A). In one extreme case, only 17.6% (15.2%–
20.0%) of IL-13-repressed transcripts were elevated in lesional skin
(subject 4284; Figure 3A), and yet at the opposite extreme, 86.8%
(84.7%–88.9%) of IL-13-repressed transcripts were elevated in
lesional skin from another patient (subject 4177; Figure 3A). This
latter type of pattern was closely associated with weak inflamma-
tory signatures (Figure 3A). A comparable trend also emerged
among cytokine-induced transcripts (e.g., IFN-a-, TNF-a-, IL1-a-,
IL17A- and IFN-c-induced), with subjects assigned to weak/
moderate inflammatory sub-groups exhibiting the weakest eleva-
tion of cytokine-induced transcripts in lesional skin samples
(Figures 3B, 3C, 4A–4C). To further assess inflammatory-cytokine
relationships, we scanned all 1312 two-way combinations between
gene expression signatures associated with the 41 cell types and
signatures associated with the 32 sets of cytokine-responsive
transcripts. This identified 949 cases in which there was significant
correlation between an inflammatory and cytokine signature
(Spearman rank correlation, n=62 subjects; P,0.05; Figure S11).
For example, subjects with elevated expression of TNF-induced
transcripts in PP skin also tended to have elevated expression of
dendritic cell-associated transcripts in PP skin (rs=0.75,
P=1.92610
212; Figure S12A). Likewise, subjects with decreased
expression of TNF-repressed transcripts in PP skin tended to have
increased expression of monocyte-associated transcripts in PP skin
(rs=20.57, P=1.24610
26; Figure S12B).
Heightened inflammatory and cytokine signatures are
only weakly associated with increased psoriasis
susceptibility loci risk allele frequency (REL, TRAF3IP2,
NOS2 and FBXL19; n=62 patients)
Our results show that psoriasis lesions can be assigned to sub-
groups based upon the inflammatory infiltrate or cytokine activity
signatures embedded within genome-wide expression profiles (see
Table S2 summary). We evaluated whether abundance of psoriasis
risk alleles differed between patients assigned to these sub-groups
(Figures S13 and S14). Risk alleles for two single nucleotide
polymorphism (SNP) markers (rs13017599/REL and rs842636/
REL) were more frequent among the 23 subjects belonging to the
strong inflammatory signature group, as compared to the 15
subjects belonging to either the moderate or weak inflammatory
group (Cliff’s delta=0.37; P,0.039; FDR-adjusted P=0.46;
Figure S13). However, one SNP marker followed the opposite
trend (rs610604/TNFAIP3), with elevated risk allele burden
among subjects assigned to the weak inflammatory sub-group
(delta=20.382; P=0.017; FDR-adjusted P=0.46; Figure S13). A
cumulative risk score was calculated by fitting a logistic regression
model to risk allele burden scores across 44 psoriasis susceptibility
loci (see values in right margin of Figure S13). On average, this
cumulative genetic risk score was lower among subjects assigned to
the strong inflammatory group, but this difference was of threshold
significance (54.562.4 versus 62.463.4; P=0.063, Wilcoxon
rank-sum test; P=0.067, two-tailed t-test).
These analyses were repeated with respect to the IL-13-weak
(n=31) and IL-13-strong (n=31) sub-groups (Figure S14). We
identified three loci for which risk alleles were more frequent in IL-
13-strong subjects, including rs13210247/TRAF3IP2 (Cliff’s del-
ta=20.226; P=0.012; FDR-adjusted P=0.363), rs4795067/
NOS2 (Cliff’s delta=20.302, P=0.025, FDR-adjusted P=0.363)
and rs12924903/FBXL19 (Cliff’s delta=20.289; P=0.029;
FDR-adjusted P=0.363) (Figure S14). However, with respect to
two other psoriasis susceptibility loci (rs1008953/SDC4 and
rs2082412/IL12B), risk alleles were enriched in subjects with IL-
13-weak patterns (Cliff’s delta $0.25; P#0.045; FDR-adjusted
P#0.40) (Figure S14). On average, subjects associated with IL-13-
strong and IL-13-weak patterns had similar cumulative genetic risk
scores (59.162.7 versus 58.762.3; P=0.91; two-tailed t-test).
Discussion
Treatment protocols for chronic plaque psoriasis do not, at
present, draw upon patient-specific genomic data, and there is
limited basis for predicting patient responses to systemic therapies.
Based upon transcriptome data from 62 patients, we have shown
that 24% of lesional skin samples are associated with a weakened
inflammatory infiltrate signature, suggestive of decreased infiltra-
tion primarily by macrophages and dendritic cells along with
monocytes, T-cells and NK cells. Furthermore, half of lesional
samples exhibit an ‘‘IL-13-weak’’ signature that is broadly
consistent with localized attenuation of the cytokine network.
20% of lesions, moreover, were associated with both groups, with
combined diminution of inflammatory and cytokine signatures
(e.g., see subjects 4177, 4165, 4089, 3690 and 4162 in Figures 1
and 2). Psoriasis lesions, therefore, may look very similar clinically,
with their hallmark features, and likewise, standard immunohis-
tochemistry may not uncover distinctions between lesional skin
samples. We have shown, however, that high dimensional
transcriptome data can be exploited to effectively uncover a level
of ‘‘hidden heterogeneity’’, which has not been previously
described for chronic plaque psoriasis. This provides a new
method for stratifying lesional samples according to inflammatory
and cytokine activity, which can be developed further to provide a
bona fide clinical application for patient-specific transcriptome data,
with the aim of predicting patient responses to treatment.
Psoriasis plaque formation is very complex and incompletely
understood. It involves an interaction between inflammatory and
resident tissue cells with both positive and negative feedback
cycles, primarily mediated by various growth factors and cytokines
[1,23]. Interactions between T-cells, dendritic cells, macrophages
and keratinocytes appear to play a key role, particularly through
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model has guided development of often effective therapies that
block interactions between T-cells and antigen presenting cells,
along with anti-cytokine treatments, such as anti-TNF and anti-
p40 (ustekinumab) [23]. However, short-term (10–12 weeks)
response rates to these therapies vary from 50–80% [26],
Figure 3. Distribution of IL-13, IFN-a and TNF gene expression signatures among lesional skin samples from 62 patients. We
identified sets of 1000 transcripts that were (A) repressed by IL-13 treatment of cultured keratinocytes, (B) induced by IFN-a treatment of
keratinocytes and (C) induced by TNF treatment of keratinocytes. For each set and patient, we calculated the percentage of transcripts elevated in
lesional (PP) samples as compared to paired non-lesional (PN) samples. In (A)–(C), subjects are ordered according to the estimated proportion of
cytokine-responsive transcripts elevated in PP skin relative to PN skin. Yellow boxes outline a 95% confidence interval for this proportion. Label colors
are consistent with those in Figure 1 (strong, moderate or weak inflammatory groups). Asterisk symbols identify subjects with IL-13-weak patterns
(Figure 2).
doi:10.1371/journal.pone.0034594.g003
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model will be sufficient for understanding the complete spectrum
of chronic plaque psoriasis. In our cohort of 62 subjects, a
significant TNF cytokine signature was detected in only 18
patients (29%) (Figures 2 and S7). Moreover, among 1000
transcripts induced by TNF in cultured keratinocytes, the
proportion of such transcripts elevated in lesional skin varied
from 43.4% (subject 4165; 95% CI: 40.3–45%) to 75.3% (subject
4284; 95% CI: 72.6%–78.0%) (Figure 3C). Subjects exhibiting the
weakest TNF signatures were associated with the IL-13-weak
Figure 4. Distribution of IL1-a, IL-17A and IFN-c gene expression signatures among lesional skin samples from 62 patients. We
identified three sets of 1000 transcripts that were (A) induced by IL1-a treatment of cultured keratinocytes, (B) induced by IL-17A treatment of
keratinocytes and (C) induced by IFN-c treatment of keratinocytes. For each set and patient, we calculated the percentage of transcripts elevated in
lesional (PP) samples as compared to paired non-lesional (PN) samples. In (A)–(C), subjects are ordered according to the estimated proportion of
cytokine-responsive transcripts elevated in PP skin relative to PN skin (as described in the Figure 3 legend).
doi:10.1371/journal.pone.0034594.g004
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cytokine network within this group that is not necessarily limited to
the TNF cytokine alone (Figure 3C). This suggests that in many
patients, absence of a strong TNF signature may not reflect
reduced abundance of TNF per se, but rather an overall
attenuation of amplifying effects that other cytokines have on the
sensitivity of resident cells to TNF signals [24]. More work is
needed to determine whether such subjects are particularly non-
responsive or apt to develop worsened disease status upon
treatment with anti-TNF treatments [3,4].
We noted strong variability with respect to the behavior of IL-
13-responsive transcripts in lesional skin samples (Figure 3A), and
overall, IL-13-responsive transcripts best differentiated the two
main groups of cytokine signatures in our cohort (Figure 2). IL-13
is a Th2-type cytokine produced by activated T-cells, which can
have anti-inflammatory effects in certain cell types [27], but which
also stimulates IL-6 production in cultured keratinocytes [28]. The
role of IL-13 in the initiation or maintenance of psoriasis lesions is
not yet clear. Initial studies showed that IL-13 mRNA levels do not
differ significantly between lesional and non-lesional skin samples
from psoriasis patients [29,30]. Subsequent studies confirmed this
result, but also showed that mRNA encoding the a1 chain of the
IL-13 receptor is over-expressed in lesional skin relative to normal
skin from healthy controls [31], and further demonstrated that IL-
13 is elevated in synovial fluid of patients with psoriatic arthritis
[32]. Moreover, a large genome-wide association study, including
3523 cutaneous-only psoriasis cases, 1755 psoriatic arthritis cases,
and 5942 unaffected controls, reported that both cutaneous-only
psoriasis and psoriatic arthritis were associated with an exonic IL-
13 locus on chromosome 5q31 (rs20541) [33]; however, recent
analyses suggest that this association is stronger with respect to
psoriatic arthritis, or even specific to psoriatic arthritis with no
significant association to cutaneous-only psoriasis [34,35].
We have identified a range of inflammatory and cytokine
activity phenotypes associated with the clinical presentation of
chronic plaque psoriasis. Factors that account for this heteroge-
neity, however, are not completely understood [6,7]. Potentially,
some heterogeneity we identified may reflect distinct developmen-
tal stages of psoriasis lesions, with some lesions biopsied during an
early initiation stage and others biopsied at a late resolving stage
[1,23]. One report, for instance, has commented that intensity of
immunohistochemical IL-13Ra1 staining tends to be stronger in
psoriasis lesions that are larger in size [31], which potentially, may
reflect differential activation of IL-13-sensitive pathways across
stages of plaque development. In addition, the range of molecular
phenotypes we observed may be associated with the anatomic
region from which lesional biopsies were obtained (e.g., abdomen
versus arms), thickness of individual plaques, or the specific region
of a plaque that is biopsied (e.g., edge versus center). More
extensive studies will thus be necessary to determine whether
variability between patients, as documented by our analysis, is in
excess of the intra-individual variation attributable to these
sources, and more generally to assess how well a single biopsy
can represent the individual patient. There is, however, ample
evidence to support the genetic basis of psoriasis, along with
marked clinical disparities among patients in terms of severity,
clinical course and treatment responses [3–7]. Despite the need for
further data, therefore, we expect that patient-specific factors at
least partially contribute to the range of molecular phenotypes
observed in psoriasis lesions. These factors may relate to the
unique genetic characteristics of individual patients, but may also
stem from other (non-genetic) sources of variation influencing
systemic or local intensity of inflammatory and cytokine responses,
such as body mass index or smoking history [36,37].
We thus anticipate that methods developed in this study can, in
further work, be applied to larger datasets to provide a more fine-
scale characterization of heterogeneity within patient cohorts, with
the aim of better pinpointing the specific inflammatory and
cytokine factors that drive and maintain disease states in specific
patient cohorts. Additionally, it will be of interest to determine
whether, in larger patient samples, heterogeneity of inflammatory
and cytokine gene expression patterns is significantly correlated
with response patterns of patients to conservative or biologic
therapies, since this would facilitate proactive disease management
in clinical settings and better targeting of therapies to the unique
characteristics of individual patients. Future work in this direction
can provide insights into how patient-specific genetic and
environmental factors combine to shape disease mechanisms that
underlie this inflammatory skin disorder.
Materials and Methods
Ethics statement
All procedures were conducted according to the Declaration of
Helsinki principles. Informed written consent was obtained from
human subjects under protocols approved by the University of
Michigan institutional review board (HUM00037994).
Patient cohort and sample collection
Sample collection and processing methods followed in this study
have been summarized in a previous report [12]. A total of 62
patients were included in the main cohort (30 males and 32
females), where each patient had one or more psoriasis plaques not
limited to the scalp area. For cases in which only one plaque was
present, a patient was admitted when that plaque occupied more
than 1% of the body surface area. 6 mm punch biopsies of lesional
(PP) and non-lesional (PN) regions were obtained from each
patient under local anesthesia, with all non-lesional biopsies
obtained from the buttocks and at least 10 cm away from the
nearest active psoriasis plaque. For lesional samples, biopsies were
preferentially taken near the central region of active plaques,
except in cases where the center was poorly defined due to an
irregular boundary. Regions near the edge of individual plaques
were avoided to ensure that uninvolved skin was not included
within the lesional sample. We utilized non-lesional PN samples
from psoriasis patients as controls for identifying transcripts with
increased or decreased expression in lesional skin. This approach
provides a matched non-lesional sample for each psoriasis patient,
which we have used to control for variation with respect to patient-
specific factors (e.g., age, sex, gender, etc.). We note, however, that
gene expression patterns associated with uninvolved skin from
psoriasis patients are expected to differ from those of normal skin
from healthy individuals without psoriasis [12].
Among all 62 patients, the average total body surface area
covered with psoriasis lesions was 14.2%61.7% (minimum: 1%;
maximum 62%; including palms, head, limbs and trunk). Average
surface area did not differ significantly among those with weak,
moderate and strong inflammatory patterns (P=0.96, ANOVA),
and likewise, the average surface area did not differ among those
with IL-13-weak and IL-13-strong cytokine signatures (P=0.56,
ANOVA). All subjects were between 21 and 69 years of age
(average: 49.261.5 years), and age did not differ significantly
between inflammatory or cytokine groups (P$0.36, ANOVA).
Patients were advised not to use systemic medications for at least 2
weeks prior to sample biopsies, and not to apply topical treatments
for at least 1 week prior to biopsies. Our cohort included patients
that had previously been treated with the systemic medications
Methotrexate (n=8), Enbrel (n=6), Cyclosporine (n=2), Humira
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Stelara (n=1). The expected half-life of each medication is less
than 2 weeks [38–45], and we noted few cases in which prior
treatment history was significantly associated with inflammatory or
cytokine signature scores (Figure S15).
Microarray analysis of gene expression
RNA was extracted from lesional (PP) and non-lesional (PN)
skin biopsies and processed according to standard Affymetrix
protocols [46]. Genome-wide expression in all samples was
evaluated using the Human Genome U133 2.0 oligonucleotide
array platform (54613 probe sets per array). Annotation for this
array platform was obtained from the NetAffx database (Release
31) [47]. The MIAME compliant raw data has been deposited in
the Gene Expression Omnibus database and is available under
accession GSE13355. We have also analyzed an independent
dataset available under accession GSE14905 (Figures S5 and S8)
[11], which included PP and PN hybridizations involving the same
Affymetrix Human Genome U133 2.0 array platform. The RMA
algorithm was used to calculate normalized expression scores for
each dataset and for data used to generate inflammation profiles
and cytokine activity signatures (see below) [48]. Normalized
expression scores for PP and PN samples available from
GSE13355 were adjusted for sex and batch effects prior to further
analyses. All analyses were conducted using the R statistical
software package (with extension packages: ClassDiscovery, fpc,
limma, mvoutlier, orddom, outliers, proxy, RColorBrewer,
RSQLite, sciplot) [49].
Calculation of inflammation profiles
Inflammation profiles (Figures 1, S1 and S5) were calculated
following the methodology described by Swindell et al. [18]. In
brief, we identified ‘‘signature transcripts’’ for each of 354 human
cell populations, based upon array samples obtained from the
Gene Expression Omnibus database (Human Genome U133 2.0
platform). A selected fraction of these cell populations was used to
generate the columns in Figures 1, S1 and S5 (e.g., blood-derived
CD4+ T-cells, B-cells, keratinocytes; selection criteria are
described below). Because most cell types shown in Figures 1, S1
and S5 represent infiltrating immune cells, we have referred to
these patterns as ‘‘inflammatory infiltrate signatures’’ and
‘‘inflammation profiles’’, consistent with terminology used previ-
ously [18]. We note, however, that some populations we
considered are in fact resident cell types (e.g., fibroblasts,
keratinocytes and epidermis) or sources of immune cells that
harbor or give rise to infiltrating cell types but do not directly
infiltrate lesional psoriatic skin (e.g., bone marrow).
Signature transcripts for each cell population were identified
based upon a two-sample comparison between replicate array
hybridizations involving a given cell population (n=4.43 replicates
per cell population on average) and a reference set of 21 array
samples hybridized with cDNA generated from human skin tissue
(see GEO accession ids GSE7307, GSE6281, GSE16161,
GSE17539 for description of reference samples). To identify
signature transcripts highly expressed within each cell population
(relative to human skin), we first used empirical Bayes methods to
calculate p-values for all transcripts [50]. Transcripts were then
filtered to include only those with higher expression (on average) in
the cell population relative to normal skin, and from among this
filtered set of transcripts, the top 2000 probe sets with the most
significant p-values were isolated. These 2000 transcripts were
then ranked according to the fold-change estimate (i.e., average
expression in the cell population of interest/average expression in
reference skin samples), and the top 1000 of these transcripts (with
highest fold-change) were identified and designated as signature
transcripts for that cell population. Supplemental data include two
example lists of signature transcripts that were generated using this
methodology (associated with keratinocytes and blood-derived
CD4+ T-cells) (Tables S3 and S4).
Inflammation profiles were next calculated for individual
patients based upon the 1000 signature transcripts identified for
each of the 354 cell populations. For each patient and cell
population, we calculated the fraction of signature transcripts
elevated in lesional skin as compared to non-lesional skin (i.e., no.
PP-elevated signature transcripts/no. PP-decreased signature
transcripts). Significance of this ratio was evaluated according to
two criteria [18]. First, we tested whether each ratio was
significantly large based upon Fisher’s exact test (with p-values
adjusted among all 354 cell populations using the conservative
Holm method). Secondly, we tested whether a significantly large
ratio was obtained (Fisher’s exact test) based upon a subset of the
original 1000 probe sets, which had been filtered to exclude any
signature transcripts of more highly-ranked cell populations (with
larger overall PP-elevated/PP-decreased ratios). A ratio was
considered significant only if both criteria were met (i.e., black
dots in Figures 1, S1 and S5) [18].
Columns in Figures 1, S1 and S5 display results for only a subset
of the 354 cell populations we considered (due to space limitation).
For instance, with respect to the category ‘‘T-cells (Blood, CD3+)’’
(first column of Figures 1, S1 and S5), a total of six different cell
populations were evaluated. In this case, and similarly in other
cases, we calculated the average signature transcript ratio across all
patients for each of the six populations (R1, R2, R3, R4, R5 and R6)
as well as the grand average of these six ratio values (R*). If R* was
larger than 1, this indicated an overall trend towards large ratios
for this cell population category, and thus as a representative to
display we chose the cell population with the largest average
signature transcript ratio across patients (i.e., max(R1, R2… R6)). If
R* was less than 1, this indicated an overall trend towards smaller
ratios for this cell population category, and thus as a representative
to display we chose the cell population with the smallest average
signature transcript ratio across patients (i.e., min(R1, R2,… ,R6)).
Cytokine activity signatures
Cytokine activity signatures (Figures 2, S7 and S8) were
generated based upon 32 sets of cytokine-responsive transcripts
identified from in vitro experiments in which keratinocytes had
been exposed to cytokines. In each experiment, genome-wide
expression in exposed and non-exposed keratinocytes was
evaluated using the Affymetrix Human Genome U133 2.0
platform. Signatures for TNF, IL-17A, IL-13, IL4, IFN-a and
IFN-c were generated based upon data from our laboratory.
These data will be submitted to Gene Expression Omnibus
following MIAME standards prior to publication of this
manuscript. All additional data was obtained from Gene
Expression Omnibus accessions GSE7216, GSE12109 and
GSE9120. For each signature, 1000 cytokine-induced or cyto-
kine-repressed transcripts were identified based upon the two-step
ranking procedure described above, where the top 2000
transcripts with lowest p-values were first identified (p-values were
generated based upon two-sample comparisons and empirical
Bayes methods), and then the top 1000 of these transcripts with the
highest (or lowest) fold-change ratio were selected and used to
generate cytokine-response signatures. With this procedure, ratios
(PP-increased/PP-decreased) represented by the color of each
square in Figures 2, S7 and S8 are based upon the same number of
transcripts (1000).
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The inflammatory and cytokine profiles shown in Figures 1, S1,
S5, 2, S7 and S8 were clustered using the complete linkage
hierarchical approach and the Euclidean distance metric. Distance
between profiles was calculated from log2-transformed ratios (i.e.,
no. PP-increased transcripts/no. of PP-decreased transcripts),
which had been standardized for each inflammatory cell
population or cytokine signature to have a mean of zero and
standard deviation of one. In Figures S13 and S14, psoriasis
susceptibility loci were clustered according to the number of risk
alleles at each loci among the 62 patients. For these analyses,
clustering was performed using the complete linkage hierarchical
approach and the Manhattan distance metric. To determine
whether any subjects should be considered outliers with respect to
either inflammatory or cytokine profiles, we first summarized
patterns across cell types (or cytokines) by considering the first two
principle component axes (Figures S3 and S10). We then tested for
the presence of an outlier with respect to each axis individually
using Grubb’s test [51]. If this test provided evidence for at least
one outlier with respect to either axis, subjects were classified as
either outliers or non-outliers in the two dimensional space using a
multivariate outlier detection algorithm [52]. This approach
identified outliers in the bivariate space using the robust
Mahalanobis distance between each subject and the bivariate
centroid, such that subjects were classified as outliers if this
distance exceeded a critical value [52].
Supporting Information
Figure S1 Sub-division of psoriasis lesions into strong,
moderate and weak inflammatory groups based on
genome-wide expression profiles. This figure is an expand-
ed version of the heatmap shown in Figure 1. Columns from
Figure 1 are a subset of those displayed in Figure S1. In both
Figures 1 and S1, the clustering pattern among subjects is
identical, and has been generated with respect to the complete
range of cell types as shown in Figure S1.
(TIF)
Figure S2 Immunohistochemical detection of T-cell
subsets, antigen presenting cells and mononuclear cells
in lesional (PP) skin samples from three patients.
Lesional skin samples from three psoriasis patients were stained
using CD3 (T-cell), CD4 (helper T-cells/monocytes), CD56 (NK
cell/activated T-cells), CD68 (monocytes/macrophages), CD11c
(dendritic cells) and elastase (neutrophil) antibodies. The three
patients evaluated are also included as separate rows in the
dendrograms from Figures 1 and 2 (i.e., subjects 6690, 7450 and
8470). Top row, with H&E, shown in 106whereas rest of images
are shown in 206magnification.
(TIF)
Figure S3 No significant outliers with respect to two
principle components derived from inflammatory sig-
nature scores. Two principle components were extracted from
the full set of inflammatory signature scores calculated for each of
the 62 patients (see Figure S1). The first principle component
accounted for 51.2% of the total variance, while the second
accounted for 18.0% of the total variance. No significant outlier
was identified with respect to either the first or second principle
component (Grubb’s test: P=0.45 and P=0.86, respectively).
Additionally, no significant bivariate outlier was detected based
upon the robust Mahalanobis distance between each point and the
bivariate centroid [52].
(TIF)
Figure S4 Average gene expression profiles of psoriasis
lesions assigned to the strong, moderate and weak
inflammatory groups. 62 psoriasis lesions were assigned to
either strong (23/62), moderate (24/62) or weak (15/62)
inflammatory groups based upon signature transcripts of immune
cell populations and their altered expression in lesional (PP) versus
non-lesional (PN) skin (see Figures 1 and S1). For each immune
cell population and each subject, we calculated the number of
signature transcripts with higher expression in PP skin relative to
PN skin, divided by the number of signature transcripts with lower
expression in PP skin relative to PN skin. The average of this ratio
was calculated for each group of patients and is shown in the figure
for each cell population (vertical axis). Error bars correspond to
the standard error of the ratio value among all subjects assigned to
a given group. The average silhouette width was calculated for
each cell population with respect to the three groups of subjects
(i.e., strong, moderate and weak groups) (top margin). This is a
summary measure of intraclass cohesion and class separation, with
values ranging from 21 to 1 [53]. The measure approaches zero
or will be negative if subjects are not well grouped with respect to a
given cell population signature (i.e., there is large variation within
groups with little separation between groups). Conversely, positive
values suggest that subjects have been placed in an appropriate
group with respect to a given cell population signature (i.e., there is
little variation within groups and large separation between groups).
(TIF)
Figure S5 Analysis of an independent dataset supports
sub-division of psoriasis lesions into strong, moderate
and weak inflammatory patterns. Inflammation profiles
were calculated for 28 patients based on PP and PN samples from
a previously published dataset (GSE14905) [11]. Each patient was
assigned to one of three sub-groups, including strong (blue labels;
6/28 subjects), moderate (red labels; 16/28 subjects) and weak
inflammatory patterns (green labels; 6/28 subjects). Inflammation
profile calculations used to generate this figure are consistent with
those used to generate Figures 1 and S1, and are further described
in the Methods section.
(TIF)
Figure S6 Distribution of keratinocyte, CD4+ T-cell and
dendritic cell gene expression signatures among lesional
skin samples from 62 patients with chronic plaque
psoriasis. We identified sets of 1000 signature transcripts highly
expressed in (A) keratinocytes, (B) CD4+ T-cells and (C) dendritic
cells, respectively. For each set of 1000 transcripts and each of 62
patients, we calculated the percentage of signature transcripts
elevated in lesional (PP) samples as compared to paired non-
lesional (PN) samples. In (A)–(C), subjects have been ordered
according to the estimated percentage of signature transcripts
elevated in PP versus PN samples. Subject label colors are
consistent with those in Figures 1 and S1, and denote assignment
to strong (blue), moderate (red) or weak (green) inflammatory
groups. An asterisk symbol is used to denote subjects with IL-13-
weak gene expression signatures (see Figures 2 and S7). The yellow
box shown for each subject outlines the 95% confidence interval
for the estimated proportion of signature transcripts elevated in the
PP sample relative to the PN sample.
(TIF)
Figure S7 Sub-division of psoriasis lesions into IL-13-
strong and IL-13-weak groups based on genome-wide
expression profiles. This figure is an expanded version of the
heatmap shown in Figure 2. Columns from Figure 2 are a subset of
those displayed in Figure S7. In both Figures 2 and S7, the
clustering pattern among subjects is identical, and has been
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signatures as shown in Figure S7.
(TIF)
Figure S8 Analysis of an independent dataset identifies
IL-13-strong and IL-13-weak psoriasis lesions. Gene
expression signatures associated with the in vitro responses of
keratinocytes to cytokine exposure were analyzed for 28 patients
based on lesional (PP) and non-lesional (PN) samples from a
previously published dataset (GSE14905) [11]. Cytokine signatures
were calculated and patients were clustered using average linkage
and the Euclidean distance metric (see Figures 2 and S7). An
asterisk symbol is used to denote 21 subjects for which the IL-13
signature approximated the ‘‘IL-13-weak’’ pattern identified in
Figures 2 and S7. All other subjects approximated the ‘‘IL-13-
strong’’ pattern identified in Figures 2 and S7. Colors within the
chart correspond to the number of cytokine-responsive transcripts
with higher expression in PP versus PN skin, divided by the
number of cytokine-responsive transcripts with lower expression in
PP versus PN skin (see legend). For IL-13-weak lesions (asterisk
symbol), this ratio is lower among IL-13-induced transcripts, but
higher among IL-13-repressed transcripts. For IL-13-strong lesions
(no asterisk), this ratio is higher among IL-13-induced transcripts,
but lower among IL-13-repressed transcripts.
(TIF)
Figure S9 Average gene expression profiles of psoriasis
lesions assigned to IL-13-weak and IL-13-strong cytokine
groups. 62 psoriasis lesions were assigned to either IL-13-weak
(31/62) or IL-13-strong (31/62) groups based upon cytokine-
responsive transcripts and their altered expression in lesional (PP)
versus non-lesional (PN) skin (see Figures 2 and S7). For each
patient, we calculated the number of cytokine-responsive tran-
scripts with higher expression in PP skin relative to PN skin,
divided by the number of signature transcripts with lower
expression in PP skin relative to PN skin. The average of this
ratio was calculated for each group of patients and is shown in the
figure (vertical axis). Error bars correspond to the standard error of
the ratio value among all subjects within a given group. The
average silhouette width was calculated for each cell population
with respect to the two groups of subjects (i.e., IL-13-weak and IL-
13-strong groups) (top margin). This is a summary measure of
intraclass cohesion and class separation, with values ranging from
21 to 1 for each cytokine signature (see Figure S4 legend) [53].
(TIF)
Figure S10 Three significant outliers with respect to
two principle components derived from cytokine signa-
ture scores (Subjects 4284, 4697 and 4163). Two principle
components were extracted from full set of cytokine signature
scores calculated for each of the 62 patients (see Figure S7). The
first principle component accounted for 60.5% of the total
variance, while the second accounted for 14.9% of the total
variance. At least one significant outlier was present with respect to
the first principle component (Grubb’s test: P=1.95610
212), but
no outliers were detected with respect to the second principle
component (Grubb’s test: P=0.07). Three significant bivariate
outliers were detected based upon the robust Mahalanobis
distance between each point and the bivariate centroid (i.e.,
subjects 4284, 4697 and 4163) [52].
(TIF)
Figure S11 Spearman correlation coefficients between
inflammatory and cytokine signature scores (n=62
patients). We calculated inflammatory signature scores with
respect to 41 cell types (Figures 1 and S1) and cytokine signature
scores with respect to 32 sets of cytokine-responsive transcripts
(Figures 2 and S7). To assess the relationship between inflamma-
tion- and cytokine-associated patterns, we estimated the Spearman
rank correlation for all 1312 two-way combinations of inflamma-
tory and cytokine signature scores. For each pairing, red colors
denote cases in which subjects with increased expression of
cytokine-responsive transcripts (left margin) in PP skin also tend to
have increased expression of transcripts highly expressed in a given
inflammatory cell type (top margin). Conversely, green colors
denote cases in which subjects with increased expression of
cytokine-responsive transcripts (left margin) in PP skin also tend to
have decreased expression of transcripts highly expressed in a given
inflammatory cell type (top margin). As an example, Figure S12
shows two examples including one positive and one negative
correlation (i.e., TNF-induced signature versus infected dendritic
cell signature, rs=0.75; TNF-repressed signature versus infected
monocyte signature, rs=20.57). Cytokine and inflammatory
signature scores in each comparison were, if necessary, adjusted
such that each score was based upon a non-overlapping set of
transcripts (i.e., any shared transcripts were filtered out prior to
calculation of scores for each subject and estimation of the
correlation coefficient). Rows and columns of the heatmap have
been clustered using complete linkage and the Euclidean distance
metric. For each set of cytokine-responsive transcripts (i.e., each
row), the largest correlation is outlined in blue while the most
negative correlation is outlined in magenta (see legend).
(TIF)
Figure S12 Shifts in the expression of TNF-responsive
transcripts in PP skin (versus PN skin) co-occur with
shifts in the expression of transcripts that are highly
expressed in dendritic cells and monocytes (n=62
subjects). We screened 1312 two-way combinations involving
inflammatory and cytokine signatures to determine which were
significantly associated among the 62 subjects included in our
cohort (Figure S11). With respect to TNF-induced transcripts, the
strongest positive association was identified with respect to the
signature calculated from transcripts with high expression in
infected dendritic cells (rs=0.75, part A). With respect to TNF-
repressed transcripts, the strongest negative association was
identified with respect to the signature calculated from transcripts
with high expression in infected monocytes (rs=20.57, part B). In
both (A) and (B), all 62 subjects included in the cohort are plotted
with respect to each cytokine and inflammatory signature. The
vertical axis indicates the proportion of TNF-responsive transcripts
elevated in PP (versus PN) skin from a given subject. The
horizontal axis denotes patterns associated with transcripts that
have high expression in (A) infected dendritic cells or (B) infected
monocytes, and corresponds to the proportion of such transcripts
elevated in PP (versus PN) skin from each subject. In both (A) and
(B), transcripts used to calculate the TNF signature for each
subject are distinct from those used to calculate the dendritic cell
(part A) or monocyte (part B) signature (i.e., any shared transcripts
were removed).
(TIF)
Figure S13 Frequency of risk alleles at 44 psoriasis
susceptibility loci in 62 patients clustered according to
inflammatory gene expression signatures. The 62 patients
included in our cohort were clustered according to inflammatory
gene expression signatures (see Figures 1 and S1; blue, red and
green labels correspond to strong, moderate and weak sub-groups,
respectively). Colors in the chart indicate whether subjects are
homozygous for psoriasis risk alleles (red), heterozygous (orange) or
non-carriers (grey), where each column corresponds to a different
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where data is not available. Susceptibility loci (columns) have been
clustered according to similarity across the 62 subjects (based on
the Manhattan distance metric). For each locus, we evaluated
whether risk alleles were more frequent in subjects associated with
strong inflammatory patterns (blue labels) relative to those
associated with weak inflammatory patterns (green labels).
Estimates of Cliff’s delta (D) are listed along the bottom margin
of the chart (21#D#1). Positive estimates (navy blue font)
indicate a higher risk allele frequency in subjects with strong
inflammatory patterns, and negative estimates (dark pink font)
indicate lower risk allele frequency in subjects with strong
inflammatory patterns. Significant estimates of D (P,0.05; prior
to FDR adjustment) are denoted by three asterisk symbols (***).
The right margin of the chart lists cumulative genetic risk scores
calculated for each subject. Cumulative genetic risk scores were
calculated by first fitting a logistic regression model, with risk allele
burden (0, 1 or 2) at the 44 loci as predictors. The model was fit
based upon marker data from an external training set of 2568
psoriasis cases and 2525 control subjects. This fitted logistic
regression model was then applied to genotype data from our 62
subjects to calculate the genetic-based probability that a subject is
a psoriasis case (though all 62 subjects are verified psoriasis cases).
Risk scores in the right margin can thus be interpreted as
probabilities, with larger values (.50) indicative of a genetic
profile more consistent with psoriasis cases (i.e., with respect to the
44 risk loci considered). For calculation of cumulative genetic risk
scores, missing data were imputed using the modal number of risk
alleles across all subjects for a given locus. Risk scores were not
calculated for subjects untyped at more than 15 loci.
(TIF)
Figure S14 Frequency of risk alleles at 44 psoriasis
susceptibility loci in 62 patients clustered according to
cytokine-specific gene expression signatures. The 62
patients included in our cohort were clustered according to gene
expression signatures representing the transcriptional response
patterns of cultured keratinocytes treated with cytokines (see
Figures 2 and S7; IL-13-weak subjects are denoted by an asterisk
symbol). The interpretation of heatmap colors and calculated
numerical values is consistent with Figure S13. However, in this
figure, estimates of Cliff’s delta (D)( 21#D#1) (bottom margin)
were generated by testing whether risk allele frequency is elevated
in IL-13-weak subjects (asterisk symbols). Positive values of D (navy
blue) denote elevated risk allele frequency in subjects assigned to
the IL-13-weak group, while negative values denote decreased risk
allele frequency in subjects assigned to the IL-13-weak group.
Significant estimates of D (P,0.05; prior to FDR adjustment) are
indicated by three asterisk symbols (***). Cumulative genetic risk
scores calculated for each subject are listed in the right margin (see
Figure S13 legend for details).
(TIF)
Figure S15 Psoriasis treatment history and its relation-
ship with inflammatory and cytokine signatures. The 62
patients in our cohort were advised not to use systemic
medications for at least 2 weeks prior to sample biopsies, and
not to apply topical treatments for at least 1 week prior to biopsies.
Patients completed a questionnaire in which they listed all
therapies previously used to treat their condition. Ten prior
treatments were reported among the 62 patients (left margin in A
and B). For each treatment, a two-sample t-test was performed
with respect to each inflammatory (part A) or cytokine (part B)
signature in order to determine whether signature scores differed
significantly among the n subjects reporting a given treatment
history (compared with all other subjects that did not report the
same treatment history). Colors correspond to the value of the T
statistic generated from each two-sample t-test. Red colors denote
a trend towards elevated signature scores among the n subjects
reporting the treatment history listed in each row (see legend).
Green colors denote a trend towards decreased signature scores
among the n subjects reporting the treatment history listed in each
row (see legend). Filled triangles denote significant T statistics
based upon FDR-corrected p-values, while open triangles indicate
significant T statistics based upon raw p-values prior to multiple
test adjustment.
(TIF)
Table S1 Steady state mRNA levels of cytokines and
their association with cytokine signature scores calcu-
lated from sets of cytokine-responsive transcripts. We
identified 32 sets of 1000 cytokine-responsive transcripts in
cultured keratinocytes (i.e., cytokine-induced or cytokine-repressed
transcripts). For each set and each of 62 patients, we calculated a
cytokine signature score, equal to the number of transcripts (of
1000) with higher expression in PP skin relative to PN skin, divided
by the number of transcripts (of 1000) with lower expression in PP
skin relative to PN skin. Additionally, for each set and each
patient, we calculated the fold-change in steady state mRNA level
between PP and PN skin. This table lists correlations between
these fold-change estimates and cytokine signature scores across
the 62 patients.
(PDF)
Table S2 Classification of 62 psoriasis lesions based
upon genome-wide expression patterns. Psoriasis lesions
from 62 patients were assigned to strong, moderate or weak
inflammatory groups (Figures 1, S1 and S4), as well as to IL-13-
strong or IL-13-weak groups (Figures 2, S7 and S9). This table lists
the number of patients assigned to each of the inflammatory-
cytokine group combinations.
(PDF)
Table S3 Set of 1000 signature transcripts with high
expression in keratinocytes relative to normal skin.
Heatmaps shown in Figures 1, S1 and S5 are based upon the
expression patterns of cell type-specific ‘‘signature transcripts’’ in
lesional (PP) and non-lesional (PN) skin samples. This table
provides an example of the 1000 signature transcripts associated
with one cell type (keratinocytes).
(PDF)
Table S4 Set of 1000 signature transcripts with high
expression in (blood-derived) CD4+ T-cells relative to
normal skin. Heatmaps shown in Figures 1, S1 and S5 are
based upon the expression patterns of cell type-specific ‘‘signature
transcripts’’ in lesional (PP) and non-lesional (PN) skin samples.
This table provides an example of the 1000 signature transcripts
associated with one cell type (blood-derived CD4+ T-cells).
(PDF)
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